CA2813743C - Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same - Google Patents

Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same Download PDF

Info

Publication number
CA2813743C
CA2813743C CA2813743A CA2813743A CA2813743C CA 2813743 C CA2813743 C CA 2813743C CA 2813743 A CA2813743 A CA 2813743A CA 2813743 A CA2813743 A CA 2813743A CA 2813743 C CA2813743 C CA 2813743C
Authority
CA
Canada
Prior art keywords
carbon atoms
formula
compound
side chain
exch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2813743A
Other languages
English (en)
French (fr)
Other versions
CA2813743A1 (en
Inventor
Aleem Gangjee
Larry H. Matherly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Duquesne University of the Holy Spirit
Original Assignee
Wayne State University
Duquesne University of the Holy Spirit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University, Duquesne University of the Holy Spirit filed Critical Wayne State University
Publication of CA2813743A1 publication Critical patent/CA2813743A1/en
Application granted granted Critical
Publication of CA2813743C publication Critical patent/CA2813743C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2813743A 2010-10-12 2011-10-10 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same Active CA2813743C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/902,310 2010-10-12
US12/902,310 US20110082158A1 (en) 2008-10-01 2010-10-12 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
PCT/US2011/055584 WO2012051105A2 (en) 2010-10-12 2011-10-10 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same

Publications (2)

Publication Number Publication Date
CA2813743A1 CA2813743A1 (en) 2012-04-19
CA2813743C true CA2813743C (en) 2022-11-08

Family

ID=45938910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2813743A Active CA2813743C (en) 2010-10-12 2011-10-10 Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same

Country Status (5)

Country Link
US (1) US20110082158A1 (https=)
EP (1) EP2627332A4 (https=)
JP (1) JP2014504258A (https=)
CA (1) CA2813743C (https=)
WO (1) WO2012051105A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
WO2016089670A1 (en) * 2014-12-02 2016-06-09 Eli Lilly And Company 1 -oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors in the treatment of cancers
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503919A (ja) * 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
JPH03173890A (ja) * 1989-09-21 1991-07-29 Takeda Chem Ind Ltd ピロロ［２，３―ｄ］ピリミジン誘導体，その製造法，用途及び中間体
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
US4996206A (en) * 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
JPH04117381A (ja) * 1989-12-20 1992-04-17 Takeda Chem Ind Ltd 縮合複素環化合物，その製造法，用途及び中間体
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
JPH0578362A (ja) * 1990-01-16 1993-03-30 Takeda Chem Ind Ltd 縮合複素環化合物，その製造法，用途及び中間体
US5939420A (en) * 1991-04-08 1999-08-17 Duquesne University Of The Holy Ghost Pyrrolo 2,3d!derivatives
JP3144903B2 (ja) * 1991-08-21 2001-03-12 エーザイ株式会社 縮合ピリミジン誘導体
JPH06172358A (ja) * 1991-12-27 1994-06-21 Takeda Chem Ind Ltd 縮合ピリミジン誘導体、その製造法および用途
WO1998008382A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
DK1109560T3 (da) * 1998-09-04 2003-11-03 Agouron Pharma Som AICARFT-inhibitorer anvendelige forbindelser
CA2459224C (en) * 2001-09-03 2012-05-08 Takeda Chemical Industries, Ltd. 1,3-benzothiazinone derivatives and the use thereof
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
US8030319B2 (en) * 2005-02-10 2011-10-04 Duquesne University Of The Holy Ghost Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2 3-d]pyrimidines
CN101195625A (zh) * 2007-12-06 2008-06-11 上海交通大学 用于抗肿瘤药物抗叶酸剂及其盐和中间体
US8252804B2 (en) * 2008-10-01 2012-08-28 Duquesne University Of The Holy Spirit Selective proton coupled folate transporter and folate receptor, and GARFTase inhibitor compounds and methods of using the same

Also Published As

Publication number Publication date
JP2014504258A (ja) 2014-02-20
WO2012051105A2 (en) 2012-04-19
CA2813743A1 (en) 2012-04-19
WO2012051105A3 (en) 2013-10-24
EP2627332A2 (en) 2013-08-21
US20110082158A1 (en) 2011-04-07
EP2627332A4 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
CA2813743C (en) Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same
CN100528874C (zh) 吡咯并[2,3d]嘧啶组合物及其应用
KR100840727B1 (ko) 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
US11053252B2 (en) Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of using the same
EA007254B1 (ru) Соединения, специфические к аденозиновому а, аи арецептору, и их применение
EP2826780B1 (en) Thieno[2,3-d]pyridazine derivatives and therapeutic use thereof for protein kinase inhibition
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
JP6343034B2 (ja) ナフチリジンジオン誘導体
EP3452484B1 (en) Certain protein kinase inhibitors
WO2018121774A1 (zh) 一种选择性抑制激酶化合物及其用途
ES2928919T3 (es) Compuestos heteroaromáticos como inhibidores de vanina
TW201623226A (zh) 化合物
CN111670188B (zh) 用于治疗纤维化的化合物和组合物
US9868750B2 (en) 4,5-diarylimidazole derivatives as HDAC inhibitors
KR20030051890A (ko) 아데노신 ａ₁, ａ₂ａ 및 ａ₃ 수용체에 특이적인 화합물및 그의 용도
HK1013402A (en) Use of hcp specific compounds to enhance erythropoiesis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160927